White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range ₹510.44 – ₹1,579 · fair‑value band ₹900.88 – ₹1,744 · the ₹889.70 price screens below the ₹1,388 fair value. Dashed = 300-day average. As of Aug 18, 2026.
524816 (524816) currently trades at ₹889.70, while our model-based Fair Value estimate is ₹1,388, implying the stock looks roughly 56.0% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Net debt stands at ₹5.1B. The stock trades on a trailing P/E of 28.4 (as of Aug 18, 2026). Fundamentals as of Aug 18, 2026
Our scenario range runs from ₹900.88 (bear case) to ₹1,744 (bull case); at ₹889.70, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 13% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at 56%, 524816 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Free cash flow₹13.8BFY2025
P/E ratio28.4as of Aug 18, 2026
EPS (TTM)₹25.29
Net debt₹5.1BFY2025
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality64/100
Of which business quality 64
· Market factors (momentum, volatility) 37
Profitability62
Margins and returns on capital today
Quality Growth34
Are margins and returns improving?
Cashflow80
Earnings quality: real cash, not paper profit
Fin. Strength80
Balance sheet, leverage, solvency risk
Investment19
Disciplined investing over empire-building
Low Volatility52
Calm price path (market factor)
Momentum33
Price trend over the last 3–12 months (market factor)
52W Momentum28
Distance to the 52-week high (market factor)
Net Issuance85
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
524816 reported revenue of ₹40.8B in FY2025 versus ₹19.4B in FY2021, a compound +20.3%/yr. Reported net income was ₹14.2B in FY2025, compounding +70.0%/yr from FY2021.
Growth Quality 84/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
₹40.8B
Latest YoY
−7.9%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.6%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.7%
Avg. growth/yr (10Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
As of Aug 18, 2026, our model estimates a fair value of ₹1,388 versus a price of ₹889.70, about +56% (undervalued).
What is the fair value of 524816?
Our model-based fair value for 524816 is ₹1,388 (as of Aug 18, 2026), built from audited fundamentals. The current price is ₹889.70.
What is the quality score of 524816?
524816 has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the net profit margin of 524816?
The net profit margin of 524816 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
14 days Pro free · no card
Track 524816 and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
or
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
